Divis Laboratories Ltd (DIVISLAB) Q1 FY27 Results Analysis: PAT Surges 66%, Revenue Jumps 28%
Divis Laboratories Ltd reported Q1 FY27 numbers with revenue of Rs. 3,080.00 Cr (+27.80% YoY) and PAT growth of +65.50% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 01, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 3,080.00 Cr (+27.80% YoY) |
| PAT (Q1) | Rs. 902.00 Cr (+65.50% YoY) |
| EBITDA margin | 40.75% (+1050 bps YoY) |
| EPS (Q1) | Rs. 33.95 (+65.69% YoY) |
| Market cap | Rs. 213,861.49 Cr |
| CMP | Rs. 8,056.00 |
Quarter Snapshot
Divis Laboratories delivered a record Q1 with revenue up 27.8% YoY and PAT up 65.5%, beating its own annual guidance on both revenue and margin. The Biosecure Act provides a structural tailwind, and operating leverage is evident. However, the large inventory drawdown and forex headwind warrant monitoring, as margin expansion may partly reverse.
Key Investment Insights
Key Positives
- Consolidated revenue grew 27.8% YoY to Rs.3,080 Cr, a record for any Q1.
- PAT grew 65.5% YoY to Rs.902 Cr, also a Q1 record.
- EBITDA margin (P&L-derived) expanded 10.5 pp YoY to 40.75%.
- EBIT margin of 38.51% exceeded management's guided range of 32-32.5%.
- Custom synthesis momentum and the Biosecure Act provide structural growth tailwinds.
- Operating leverage visible as employee cost and other expenses declined as a % of revenue.
Risk Factors
- Forex swung from a gain of Rs.39 Cr to a loss of Rs.7 Cr YoY, a headwind of ~Rs.46 Cr.
- Gross material cost as % of revenue rose sharply from 41.91% to 48.80% YoY, indicating input cost pressure.
- The large inventory drawdown of Rs.517 Cr (vs Rs.54 Cr) is a non-cash benefit that may normalize, pressuring future margins.
- Cost of materials consumed increased 48.81% YoY, outpacing revenue growth of 27.8%.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.